

# Lionel Apetoh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724009/publications.pdf>

Version: 2024-02-01

122  
papers

29,795  
citations

21215

62  
h-index

20625

120  
g-index

130  
all docs

130  
docs citations

130  
times ranked

39295  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T <sub>H</sub> 1 and T <sub>H</sub> 9 cells. , 2022, 10, e003459.		21
2	<scp>NLRP6</scp> negatively regulates type 2 immune responses in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3320-3336.	2.7	4
3	Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. Cancer Immunology Research, 2022, 10, 900-916.	1.6	2
4	The Tumor Microenvironment Impairs Th1 IFN $\gamma$ Secretion through Alternative Splicing Modifications of <i>Irf1</i> Pre-mRNA. Cancer Immunology Research, 2021, 9, 324-336.	1.6	8
5	Harnessing TH9 cells in cancer immunotherapy. Seminars in Immunology, 2021, 52, 101477.	2.7	3
6	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (edition	4.3	1,430
7	An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets. Cell Reports, 2020, 33, 108433.	2.9	54
8	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	1.8	8
9	Anticancer effects of the microbiota: how the microbiome shapes the development of IL-9-producing T cells. British Journal of Cancer, 2020, 123, 497-498.	2.9	3
10	How does autophagy affect tumor-infiltrating immune cells?. , 2020, , 75-84.		0
11	Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functions. Nature Communications, 2019, 10, 2924.	5.8	34
12	Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Research, 2019, 79, 5958-5970.	0.4	55
13	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20
14	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers, 2019, 11, 860.	1.7	75
15	HSP70 is a negative regulator of NLRP3 inflammasome activation. Cell Death and Disease, 2019, 10, 256.	2.7	81
16	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	5.8	189
17	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. OncoImmunology, 2018, 7, e1433981.	2.1	167
18	The Secrets of T Cell Polarization. , 2018, , 69-95.		0

#	ARTICLE	IF	CITATIONS
19	Selective autophagy restricts IL-9 secretion from TH9 cells: relevance in cancer growth. <i>Cell Cycle</i> , 2018, 17, 391-392.	1.3	8
20	STING-dependent sensing of self-DNA drives silica-induced lung inflammation. <i>Nature Communications</i> , 2018, 9, 5226.	5.8	176
21	Cell-Intrinsic Roles for Autophagy in Modulating CD4 T Cell Functions. <i>Frontiers in Immunology</i> , 2018, 9, 1023.	2.2	43
22	Rationale for stimulator of interferon genesâ€‘targeted cancer immunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 86-97.	1.3	47
23	Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. <i>Cell Reports</i> , 2017, 19, 746-759.	2.9	104
24	Immunotherapeutic properties of chemotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 83-88.	1.7	30
25	Carob leaf polyphenols trigger intrinsic apoptotic pathway and induce cell cycle arrest in colon cancer cells. <i>Journal of Functional Foods</i> , 2017, 33, 112-121.	1.6	36
26	Danger signals: Chemotherapy enhancers?. <i>Immunological Reviews</i> , 2017, 280, 175-193.	2.8	50
27	Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells. <i>Nature Communications</i> , 2017, 8, 559.	5.8	67
28	Signalling strength determines proapoptotic functions of STING. <i>Nature Communications</i> , 2017, 8, 427.	5.8	321
29	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1363139.	2.1	60
30	IRF8-dependent molecular complexes control the Th9 transcriptional program. <i>Nature Communications</i> , 2017, 8, 2085.	5.8	43
31	TH9 cells in anti-tumor immunity. <i>Seminars in Immunopathology</i> , 2017, 39, 39-46.	2.8	63
32	Protein kinase C $\delta$ controls type 2 innate lymphoid cell and TH2 responses to house dust mite allergen. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1650-1666.	1.5	23
33	IL-27-Induced Type 1 Regulatory T-Cells Produce Oxysterols that Constrain IL-10 Production. <i>Frontiers in Immunology</i> , 2017, 8, 1184.	2.2	34
34	Phenolic extract from oleaster ( <i>Olea europaea</i> var. <i>Sylvestris</i> ) leaves reduces colon cancer growth and induces caspase-dependent apoptosis in colon cancer cells via the mitochondrial apoptotic pathway. <i>PLoS ONE</i> , 2017, 12, e0170823.	1.1	28
35	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410
36	<i>Enterococcus hirae</i> and <i>Barnesiella intestinihominis</i> Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. <i>Immunity</i> , 2016, 45, 931-943.	6.6	645

#	ARTICLE	IF	CITATIONS
37	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX+Bevacizumab Drug Treatment Regimen. <i>Cancer Research</i> , 2016, 76, 5241-5252.	0.4	203
38	Protection against malaria in mice is induced by blood stage-arresting histamine-releasing factor (HRF)-deficient parasites. <i>Journal of Experimental Medicine</i> , 2016, 213, 1419-1428.	4.2	26
39	Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNF±. <i>Oncogene</i> , 2016, 35, 4611-4622.	2.6	40
40	Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1054598.	2.1	144
41	Stress-Induced Depressive Behaviors Require a Functional NLRP3 Inflammasome. <i>Molecular Neurobiology</i> , 2016, 53, 4874-4882.	1.9	134
42	Human ectonucleotidase-expressing CD25 <sup>high</sup> Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. <i>Oncolmmunology</i> , 2016, 5, e1055444.	2.1	39
43	AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 157-170.	2.5	85
44	Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. <i>Oncotarget</i> , 2016, 7, 9309-9321.	0.8	30
45	The immunosuppressive enzyme IL411 promotes FoxP3 <sup>+</sup> regulatory T lymphocyte differentiation. <i>European Journal of Immunology</i> , 2015, 45, 1772-1782.	1.6	41
46	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
47	Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. <i>Journal of Molecular Cell Biology</i> , 2015, 7, 351-365.	1.5	94
48	Consensus nomenclature for CD8 <sup>+</sup> T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
49	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. <i>Annals of Oncology</i> , 2015, 26, 1813-1823.	0.6	219
50	Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. <i>Cancer Research</i> , 2015, 75, 475-479.	0.4	56
51	The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. <i>Nature Immunology</i> , 2015, 16, 859-870.	7.0	312
52	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367
53	Immunogénicité de la chimiothérapie. <i>Oncologie</i> , 2015, 17, 345-353.	0.2	0
54	Radiotherapy and Immunogenic Cell Death. <i>Seminars in Radiation Oncology</i> , 2015, 25, 11-17.	1.0	354

#	ARTICLE	IF	CITATIONS
55	Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives. <i>Biomedical Journal</i> , 2015, 38, 111.	1.4	42
56	Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients. <i>PLoS ONE</i> , 2014, 9, e105907.	1.1	14
57	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
58	Liver X receptor $\hat{I}^2$ activation induces pyroptosis of human and murine colon cancer cells. <i>Cell Death and Differentiation</i> , 2014, 21, 1914-1924.	5.0	127
59	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. <i>Nature Immunology</i> , 2014, 15, 758-766.	7.0	187
60	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 19-30.	1.3	48
61	Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1098-1116.	2.5	36
62	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. <i>Science</i> , 2013, 342, 971-976.	6.0	1,580
63	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. <i>Nature Medicine</i> , 2013, 19, 57-64.	15.2	634
64	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. <i>Journal of Investigative Dermatology</i> , 2013, 133, 499-508.	0.3	75
65	Immune effects of 5-fluorouracil. <i>Oncolmmunology</i> , 2013, 2, e23139.	2.1	35
66	SOCS3 Transactivation by PPAR $\hat{I}^3$ Prevents IL-17-Driven Cancer Growth. <i>Cancer Research</i> , 2013, 73, 3578-3590.	0.4	51
67	Metallothioneins negatively regulate IL-27-induced type 1 regulatory T-cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7802-7807.	3.3	48
68	Socs3 induction by PPAR $\hat{I}^3$ restrains cancer-promoting inflammation. <i>Cell Cycle</i> , 2013, 12, 2157-2158.	1.3	8
69	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. <i>PLoS ONE</i> , 2013, 8, e65181.	1.1	103
70	Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. <i>Future Oncology</i> , 2013, 9, 469-472.	1.1	11
71	Role of IL-17 and IL-17 Family Cytokines on Tumor Development. , 2013, , 219-230.		0
72	FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. <i>Annals of Oncology</i> , 2012, 23, 2552-2561.	0.6	31

#	ARTICLE	IF	CITATIONS
73	Controversies on the role of Th17 in cancer: a TGF- $\beta$ -dependent immunosuppressive activity?. Trends in Molecular Medicine, 2012, 18, 742-749.	3.5	75
74	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity, 2012, 36, 362-373.	6.6	275
75	Role of myeloid-derived suppressor cells in tumor immunotherapy. Immunotherapy, 2012, 4, 43-57.	1.0	31
76	Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neuro-Oncology, 2012, 107, 351-358.	1.4	47
77	Contribution of IL-17 $\alpha$ -producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 491-503.	4.2	303
78	Harnessing dendritic cells in cancer. Seminars in Immunology, 2011, 23, 42-49.	2.7	53
79	Type 1 regulatory T cells (Tr1) in autoimmunity. Seminars in Immunology, 2011, 23, 202-208.	2.7	141
80	Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27. Seminars in Immunology, 2011, 23, 438-445.	2.7	142
81	In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. Journal of Pathology, 2011, 224, 389-400.	2.1	204
82	Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies. Current Molecular Medicine, 2011, 11, 365-372.	0.6	64
83	Contribution of IL-17 $\alpha$ -producing $\gamma\delta$ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine, 2011, 208, 869-869.	4.2	6
84	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2011, 208, 1331-1331.	4.2	12
85	T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. British Journal of Cancer, 2011, 105, 366-371.	2.9	56
86	Cancer, Inflammasomes, and Adjuvanticity. , 2011, , 151-163.		0
87	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2010, 207, 2187-2194.	4.2	1,652
88	Tim-3/Tim-3L Pathway as a Target for Restoring Effector Functions in Exhausted CD8 Lymphocytes in Tumors. Clinical Immunology, 2010, 135, S12.	1.4	0
89	Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 2010, 29, 482-491.	2.6	937
90	The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nature Immunology, 2010, 11, 854-861.	7.0	651

#	ARTICLE	IF	CITATIONS
91	Desirable cell death during anticancer chemotherapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 99-108.	1.8	70
92	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	3.9	761
93	Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells. <i>Journal of Immunology</i> , 2010, 185, 1383-1392.	0.4	243
94	Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity. <i>Cancer Research</i> , 2010, 70, 855-858.	0.4	326
95	Molecular Pathways in the Induction of Interleukin-27-Driven Regulatory Type 1 Cells. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 381-388.	0.5	55
96	5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 3052-3061.	0.4	1,098
97	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. <i>Seminars in Immunology</i> , 2010, 22, 113-124.	2.7	183
98	Human FOXP3 and cancer. <i>Oncogene</i> , 2010, 29, 4121-4129.	2.6	118
99	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 $\beta$ -dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009, 15, 1170-1178.	15.2	1,614
100	Witch Hunt against Tumor Cells Enhanced by Dendritic Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1174, 51-60.	1.8	11
101	Immunogenic cancer cell death: a key-lock paradigm. <i>Current Opinion in Immunology</i> , 2008, 20, 504-511.	2.4	271
102	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1579-1587.	2.0	137
103	Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008, 8, 59-73.	10.6	1,374
104	Molecular characteristics of immunogenic cancer cell death. <i>Cell Death and Differentiation</i> , 2008, 15, 3-12.	5.0	421
105	OR.13. Endogenous Danger Signals from Dying Tumor Cells Promote T-cell-dependent Antitumor Responses Which Determine the Efficacy of Conventional Anticancer Therapies. <i>Clinical Immunology</i> , 2008, 127, S8.	1.4	0
106	Cancer is not just a disease of a tissue: It is a host disease. <i>Annales D'Endocrinologie</i> , 2008, 69, 151-152.	0.6	2
107	Immunogenicity of anthracyclines: moving towards more personalized medicine. <i>Trends in Molecular Medicine</i> , 2008, 14, 141-151.	3.5	108
108	Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies. <i>Cancer Research</i> , 2008, 68, 4026-4030.	0.4	198

#	ARTICLE	IF	CITATIONS
109	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. <i>Journal of Immunology</i> , 2008, 180, 6477-6483.	0.4	44
110	Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 2413-2420.	3.2	277
111	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001.	3.9	520
112	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008, 118, 3751-3761.	3.9	56
113	IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions. <i>Blood</i> , 2008, 112, 106-106.	0.6	1
114	Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic. <i>Cancer Research</i> , 2007, 67, 7941-7944.	0.4	134
115	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007, 13, 54-61.	15.2	2,580
116	Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	15.2	2,657
117	Ecto-calreticulin in immunogenic chemotherapy. <i>Immunological Reviews</i> , 2007, 220, 22-34.	2.8	183
118	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	2.8	491
119	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. <i>Journal of Molecular Medicine</i> , 2007, 85, 1069-1076.	1.7	68
120	Links between innate and cognate tumor immunity. <i>Current Opinion in Immunology</i> , 2007, 19, 224-231.	2.4	59
121	Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. <i>Cancer Genomics and Proteomics</i> , 2007, 4, 65-70.	1.0	11
122	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	15.2	377